DE69617729D1 - Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom - Google Patents

Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom

Info

Publication number
DE69617729D1
DE69617729D1 DE69617729T DE69617729T DE69617729D1 DE 69617729 D1 DE69617729 D1 DE 69617729D1 DE 69617729 T DE69617729 T DE 69617729T DE 69617729 T DE69617729 T DE 69617729T DE 69617729 D1 DE69617729 D1 DE 69617729D1
Authority
DE
Germany
Prior art keywords
antimineralcorticoid
syndrome
compounds against
drug deactivation
deactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69617729T
Other languages
English (en)
Other versions
DE69617729T2 (de
Inventor
Francis Petit
Daniel Philibert
Nick Goeders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69617729D1 publication Critical patent/DE69617729D1/de
Publication of DE69617729T2 publication Critical patent/DE69617729T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
DE69617729T 1995-09-21 1996-09-19 Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom Expired - Fee Related DE69617729T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9511086A FR2739029B1 (fr) 1995-09-21 1995-09-21 Nouvelle application therapeutique des composes antimineralo-corticoides
PCT/FR1996/001459 WO1997010827A1 (fr) 1995-09-21 1996-09-19 Utilisation des composes antimineralocorticoides contre le syndrome de sevrage des narcotiques

Publications (2)

Publication Number Publication Date
DE69617729D1 true DE69617729D1 (de) 2002-01-17
DE69617729T2 DE69617729T2 (de) 2002-08-08

Family

ID=9482793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617729T Expired - Fee Related DE69617729T2 (de) 1995-09-21 1996-09-19 Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom

Country Status (10)

Country Link
US (3) US6147066A (de)
EP (1) EP0863760B1 (de)
JP (1) JP2000513704A (de)
AT (1) ATE209920T1 (de)
DE (1) DE69617729T2 (de)
DK (1) DK0863760T3 (de)
ES (1) ES2166001T3 (de)
FR (1) FR2739029B1 (de)
PT (1) PT863760E (de)
WO (1) WO1997010827A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726307A3 (de) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
CN1919199A (zh) * 1997-10-06 2007-02-28 利兰·斯坦福青年大学托管委员会 治疗糖皮质素功能失调相关性精神病的方法
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
AU2003230581A1 (en) * 2002-03-15 2003-09-29 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8228301B2 (en) * 2007-07-31 2012-07-24 Kent Displays Incorporated Multiple color writing tablet
US8139039B2 (en) * 2007-07-31 2012-03-20 Kent Displays, Incorporated Selectively erasable electronic writing tablet
US7960368B2 (en) * 2008-03-05 2011-06-14 Everstra, Inc. Bismethylene-17A carbolactones and related uses
WO2010138568A2 (en) * 2009-05-28 2010-12-02 Kent Displays Incorporated Writing tablet information recording device
US9134561B2 (en) 2011-11-01 2015-09-15 Kent Displays Incorporated Writing tablet information recording device
US9235075B2 (en) 2012-05-22 2016-01-12 Kent Displays Incorporated Electronic display with patterned layer
US9116379B2 (en) 2012-05-22 2015-08-25 Kent Displays Incorporated Electronic display with semitransparent back layer
US10088701B2 (en) 2013-11-01 2018-10-02 Kent Displays Inc. Electronic writing device with dot pattern recognition system
US9851612B2 (en) 2014-04-02 2017-12-26 Kent Displays Inc. Liquid crystal display with identifiers
TWI646971B (zh) * 2015-12-04 2019-01-11 鄭恩哲 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
JP2020516283A (ja) * 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
WO2019075181A1 (en) 2017-10-11 2019-04-18 Regeneron Pharmaceuticals, Inc. INHIBITION OF HSD17B13 IN THE TREATMENT OF HEPATIC DISEASE IN PATIENTS EXPRESSING PNPLA3 I148M VARIATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal

Also Published As

Publication number Publication date
US6759399B1 (en) 2004-07-06
DK0863760T3 (da) 2002-04-02
WO1997010827A1 (fr) 1997-03-27
US6147066A (en) 2000-11-14
US20040242552A1 (en) 2004-12-02
ATE209920T1 (de) 2001-12-15
FR2739029B1 (fr) 1997-11-21
ES2166001T3 (es) 2002-04-01
FR2739029A1 (fr) 1997-03-28
DE69617729T2 (de) 2002-08-08
EP0863760B1 (de) 2001-12-05
PT863760E (pt) 2002-05-31
EP0863760A1 (de) 1998-09-16
JP2000513704A (ja) 2000-10-17

Similar Documents

Publication Publication Date Title
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE69332624T2 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE239474T1 (de) Verwendung von levobupivacain
DE69821498D1 (de) Verwendung von amifostin
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE68912670D1 (de) Behandlung von Celluloseblättern.
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE293972T1 (de) Behandlung von chronischen schmerzen
ATE208201T1 (de) Verfahren zur behandlung von neoplastischen erkrankungen unter verwendung von tiazofurin und ribavirin
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
EA199800818A1 (ru) Способ лечения бессонницы
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
RU97101420A (ru) Способ лечения тонзиллита
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee